Safinamide mesylate - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for safinamide mesylate and what is the scope of patent protection?
Safinamide mesylate
is the generic ingredient in two branded drugs marketed by Aurobindo Pharma, Prinston Inc, and Mdd Us, and is included in three NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Safinamide mesylate has ninety-seven patent family members in thirty-one countries.
One supplier is listed for this compound.
Summary for safinamide mesylate
International Patents: | 97 |
US Patents: | 3 |
Tradenames: | 2 |
Applicants: | 3 |
NDAs: | 3 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 79 |
Patent Applications: | 68 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for safinamide mesylate |
What excipients (inactive ingredients) are in safinamide mesylate? | safinamide mesylate excipients list |
DailyMed Link: | safinamide mesylate at DailyMed |
Pharmacology for safinamide mesylate
Drug Class | Monoamine Oxidase Type B Inhibitor |
Mechanism of Action | Breast Cancer Resistance Protein Inhibitors Monoamine Oxidase-B Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for safinamide mesylate
US Patents and Regulatory Information for safinamide mesylate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mdd Us | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-001 | Mar 21, 2017 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Aurobindo Pharma | SAFINAMIDE MESYLATE | safinamide mesylate | TABLET;ORAL | 215902-002 | Jun 14, 2023 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Mdd Us | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-002 | Mar 21, 2017 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Prinston Inc | SAFINAMIDE MESYLATE | safinamide mesylate | TABLET;ORAL | 215739-001 | Apr 25, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for safinamide mesylate
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Cyprus | 1115286 | ⤷ Sign Up | |
Poland | 2029524 | ⤷ Sign Up | |
Spain | 2454272 | ⤷ Sign Up | |
China | 1771030 | Methods for treatment of parkinson's disease | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for safinamide mesylate
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1613296 | CR 2015 00042 | Denmark | ⤷ Sign Up | PRODUCT NAME: KOMBINATION AF SAFINAMID, HERUNDER SAFINAMID METHANSULFONAT, OG LEVODOPA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150226 |
1613296 | 92782 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: SAFINAMIDE A UTILISER EN COMBINAISON AVEC LEVODOPA/PDI, ET EVENTUELLEMENT AVEC D'AUTRES MEDICAMENTS PD , POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON; FIRST REGISTRATION DATE: 20150224 |
1613296 | C20150033 00258 | Estonia | ⤷ Sign Up | PRODUCT NAME: SAFINAMIID;REG NO/DATE: EU/1/14/984 26.02.2015 |
1613296 | 300752 | Netherlands | ⤷ Sign Up | PRODUCT NAME: SAFINAMIDE; REGISTRATION NO/DATE: EU/1/14/984 20150224 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.